Case Study

A High Volume Process For Highly Potent (HP) Active Pharmaceutical Ingredients (APIs)

Source: Alkermes Pharma Ireland Limited

The manufacture of a Highly Potent Active Pharmaceutical Ingredient (HPAPI) compound can present many challenges due to the complex handling required for toxic substances. The successful and safe manufacture of HPAPIs require the availability of a highly skilled team of staff with the right experience, the proper evaluation and training procedures being in place and the use of state-of-the-art facilities.

When taking on a HPAPI for final stage manufacture, it was important to follow a systematic approach to handle potent drugs safely.

Other essential elements included the following: defined standard operating procedures, developing and managing a staff training program, using tools to evaluate and measure exposure, designing and developing containment and controls, developing systems to verify effectiveness and finally determining and assessing the environmental impact of the active substance and associated manufacturing.

Ensuring these steps were in place was particularly important due to the fact that the Alkermes Athlone site is a multiproduct facility. Concern relating to crosscontamination with other products being manufactured had to be considered.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online